The earnings call highlighted strong financial discipline with revenue exceeding guidance and improved operating expenses, as well as positive progress in product pipeline development. However, there were notable challenges such as overall and regional revenue declines, especially in the Americas and APAC regions, impacted by tariffs and budget uncertainties. The call reflects cautious optimism with a focus on stabilizing the business and positioning for long-term growth.

Company Guidance -

Q3 2025

During the second quarter of 2025, Harvard Bioscience provided guidance indicating revenue of $20.5 million, surpassing their projection of $18 million to $20 million, largely due to increased shipments to China. The gross margin for the quarter was 56.4%, within the guidance range of 55% to 57%, although slightly down from 57.2% in the same quarter the previous year. Operating expenses were reduced by $2 million, contributing to an improved adjusted operating income of $1 million compared to $0.8 million in Q2 2024. Adjusted EBITDA increased to $1.5 million from $1.3 million the previous year, driven by lower operating expenses that offset the reduced revenue. Looking forward to Q3 2025, the company projects revenue between $19 million and $21 million, with a gross margin guidance of 56% to 58%. Additionally, the company reported strong year-to-date cash flow from operations of $5.7 million, supported by effective working capital management and reduced operating expenses, and emphasized plans to restructure their debt obligations by December 5, 2025.

Revenue Exceeds Guidance

Revenue for the second quarter was $20.5 million, exceeding the guidance of $18 million to $20 million, primarily due to higher Chinese shipments.

Improved Operating Expenses

Operating expenses declined by $2 million from the prior year, leading to an improvement in adjusted operating income to $1 million versus $0.8 million in the second quarter of 2024.

Positive Cash Flow and Debt Reduction

Year-to-date cash flow operations were strong at $5.7 million, with $2.8 million generated in the second quarter. Net debt was reduced by over $4 million from year-end to $27.9 million.

European Revenue Growth

Overall revenue in Europe increased by 9% sequentially, reflecting stronger academic shipments, and preclinical sales increased both sequentially and year-over-year.

Product Pipeline Progress

New product pipeline advancements include the SoHo Telemetry platform, VivaMARS automation pilot with Labcorp, achieving $1 million in BTX bioproduction consumable revenue, and expanding the Mesh MEA organoid platform.

Harvard Bioscience (HBIO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HBIO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	<0.01 / -	-0.02	―	―	―
Aug 11, 2025	2025 (Q2)	-0.03 / -0.01	0	―
May 12, 2025	2025 (Q1)	-0.04 / -0.01	0.02	-150.00% (-0.03)
Mar 12, 2025	2024 (Q4)	0.05 / 0.06	0.04	50.00% (+0.02)
Nov 07, 2024	2024 (Q3)	0.01 / -0.02	0.01	-300.00% (-0.03)
Aug 08, 2024	2024 (Q2)	0.05 / 0.00	0.04	―
May 07, 2024	2024 (Q1)	0.04 / 0.02	0.06	-66.67% (-0.04)
Mar 07, 2024	2023 (Q4)	0.05 / 0.04	0.04	0.00% (0.00)
Nov 07, 2023	2023 (Q3)	0.04 / 0.01	-0.01	200.00% (+0.02)
Aug 08, 2023	2023 (Q2)	0.06 / 0.04	0.05	-20.00% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HBIO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$0.53	$0.48	-9.43%
May 12, 2025	$0.32	$0.35	+9.37%
Mar 12, 2025	$0.76	$0.68	-10.53%
Nov 07, 2024	$2.82	$2.39	-15.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Harvard Bioscience (HBIO) report earnings?

Harvard Bioscience (HBIO) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Harvard Bioscience (HBIO) earnings time?

Harvard Bioscience (HBIO) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HBIO EPS forecast?

HBIO EPS forecast for the fiscal quarter 2025 (Q3) is <0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing